Literature DB >> 19564743

P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia.

Jacek Brozek1, Ewa Bryl, Anna Płoszyńska, Anna Balcerska, Jacek M Witkowski.   

Abstract

Treatment of children with acute lymphoblastic leukemia (ALL) is based on P-glycoprotein (P-gp)-dependent cytostatics. We assessed the P-gp function in blast cells as a possible prognostic factor and its influence on the overall survival. P-gp function was measured using the verapamil-sensitive Rhodamine efflux. Cell samples from 7 of 45 (16%) patients revealed rhodamine-efflux positive blasts. There were no relations between the presence of P-gp, clinical characteristics (age, sex, hepatomegaly, and splenomegaly) and initial laboratory parameters (immunophenotype, white blood cells count, and serum lactate dehydrogenase) in ALL. P-gp activity plays a negative role, both for a remission achieved on day 33 and for susceptibility to steroid therapy. Children bearing rhodamine-efflux positive blasts had a significantly shorter 5-year overall survival of 35%, as compared with 74% in those negative for P-gp function. Lack of any association with clinical characteristic and initial laboratory parameters suggests that presence of P-gp is an independent prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19564743     DOI: 10.1097/MPH.0b013e3181a974b3

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

1.  Iron containing anti-tumoral agents: unexpected apoptosis-inducing activity of a ferrocene amino acid derivative.

Authors:  Benjamin Kater; Andrea Hunold; Hans-G Schmalz; Lisa Kater; Birgit Bonitzki; Patrick Jesse; Aram Prokop
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-11       Impact factor: 4.553

2.  Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds.

Authors:  Sara Abdelfatah; Edmond Fleischer; Anette Klinger; Vincent Kam Wai Wong; Thomas Efferth
Journal:  Invest New Drugs       Date:  2019-03-15       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.